Aprea Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for APR-1051. Clearance of the IND application will allow Aprea to initiate the Phase 1 ACESOT-1051 dose escalation trial to evaluate the safety, tolerability, and preliminary efficacy of APR-1051. Enrollment of the first patient in this study is expected in the first half of 2024 with an update expected in the fourth quarter of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APRE:
- Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
- Aprea Therapeutics Updates Corporate Presentation Materials
- Aprea Therapeutics announces IND application for APR-1051
- Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
- Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
